Biodistribution Study of CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen
NCT00293215
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
1. Signed and dated Institutional Review Board (IRB)-approved informed consent before any protocol-specific screening procedures were performed.
2. Histologically confirmed malignant solid tumor that had progressed following standard therapy, or for which no standard effective treatment was available.
3. Tumor expression of Lewis-Y antigen (≥20% tumor cells positive for Lewis-Y by immunohistochemistry assay).
4. Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST), including the presence of at least one measurable lesion at least 2 cm in size suitable for 18F-FDG PET imaging.
5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
6. Life expectancy ≥ 18 weeks.
7. Age ≥18 years.
8. Recovery to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) ≤ Grade 1 toxicity from any significant effects of prior surgery, radiation therapy, and cancer therapy (except alopecia).
9. Renal test: serum creatinine ≤ 1.5 x upper limit of normal (ULN).
10. Hepatic tests: alanine aminotransferase (ALT) levels ≤2.5 x ULN and total bilirubin ≤1.5 x ULN.
11. Pancreatic tests: amylase ≤1.5 x ULN and lipase ≤ 1.5 x ULN.
12. Bone marrow tests: absolute neutrophil count (ANC) of ≥1500 mm^3 (≥1.5 x 10^9/L) and platelet count of ≥ 150,000/mm^3 (≥150 x 10^9/L).
13. For women of childbearing potential, a negative serum pregnancy test result no longer than 48 hours before the first dose of CMD-193. A woman of childbearing potential was one who was biologically capable of becoming pregnant. This included women who were using contraceptives or whose sexual partners were either sterile or using contraceptives.
14. All subjects who were not surgically sterile or postmenopausal must have agreed and committed to the use of a reliable method of birth control for the duration of the study and for 28 days after the last dose of CMD-193.
15. Willingness of female subjects to refrain from breastfeeding infants during the study or within 28 days after the last dose of CMD-193.
1. Chemotherapy, radiation therapy, other cancer therapy, or investigational agents
within 21 days of the first dose of CMD-193 (42 days if the previous chemotherapy
included nitrosoureas or mitomycin C).
2. Symptomatic or clinically active central nervous system (CNS) metastases. Subjects who
had prior treatment with radiotherapy or surgical resection for CNS metastases were
permitted if CNS metastases had remained stable and not required any treatment for at
least 3 months prior to the first dose of CMD-193.
3. Significant prior allergic reaction to recombinant human or murine proteins.
4. History of cirrhosis, current or chronic hepatitis B or C infections, or other
significant active liver disease.
5. Unstable or serious concurrent medical conditions. Examples included, but were not
limited to, bleeding gastric ulcers, gastrointestinal bleeding, hepatitis, significant
disorders of the immune system (eg, systemic lupus erythematosus), pancreatitis,
congestive heart failure, serious active infections (e.g. requiring antibiotics or
antiviral agents), unstable angina, recent myocardial infarction (within 6 months of
screening), ongoing maintenance therapy for life-threatening ventricular arrhythmia,
or uncontrolled major seizure disorder.
6. Other malignancy within 3 years prior to entry into the study, except for treated
non-melanoma skin cancer and cervical carcinoma in situ.
7. Any other condition that, in the Investigator's judgment, would have substantially
increased the risk associated with the subject's participation in this study.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Changchun, Jilin
- Beijing,
- Duarte, California
- Creve Coeur, Missouri
- Florissant, Missouri
- Saint Louis, Missouri
- Saint Louis, Missouri
- Saint Louis, Missouri
- Saint Louis, Missouri
- Saint Peters, Missouri
- Germantown, Tennessee
- Memphis, Tennessee
- Houston, Texas
- Houston, Texas
- Woodville, South Australia
- Clayton, Victoria
- Melbourne, Victoria
- Madison, Wisconsin
- Minneapolis, Minnesota
Descriptive Information | |||||
---|---|---|---|---|---|
Brief Title ICMJE | Biodistribution Study of CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen | ||||
Official Title ICMJE | Phase I Biodistribution Study of 111-Indium-CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen | ||||
Brief Summary | This was a Phase 1 dose-escalation study of CMD-193, a humanized monoclonal antibody linked to the toxin calicheamicin, in subjects with advanced tumors expressing the Lewis-Y antigen. The primary study objective was to determine the biodistribution and pharmacokinetics (PK) of 111-In-CMD-193 (i.e., CMD-193 tagged with a small amount of radioactive Indium [111-In]), with secondary objectives of determining changes in tumor metabolism and describing the antitumor responses to CMD-193. | ||||
Detailed Description | Subjects received a single infusion of 111-In-CMD-193 on Day 1. Collection of blood for PK and whole body gamma camera imaging for assessment of biodistribution and tumor uptake were performed on Days 1, 2, 3 or 4, 5 or 6, and 7 or 8 following the 111-In-CMD-193 infusion. Subjects were evaluated for safety for 3 hours post-infusion on Day 1 of each cycle, with subsequent safety assessments performed on Days 8 and 15. Blood for human anti-human antibody (HAHA) response was collected pre-infusion, prior to each subsequent cycle (every 3 weeks) and at study discontinuation. CMD-193 was administered on Day 1 of each subsequent 21-day cycle as a 60 (± 5) minute intravenous (IV) infusion at a dose of 1.0 mg/m^2 in Cohort 1 and 2.6 mg/m^2 in Cohort 2. Each subject received up to 6 cycles of CMD-193 (including the initial infusion of 111-In-CMD-193) until disease progression, unacceptable toxicity, or withdrawal of consent. Up to 6 additional cycles of CMD-193 were permitted if approved by the Sponsor in subjects who tolerated CMD-193 treatment and had evidence of response. Pretreatment medications (e.g., paracetamol, promethazine hydrochloride) were to be administered to reduce the incidence and severity of an anticipated infusion syndrome characterized by fever and chills, and less commonly hypotension. Restaging by computed tomography (CT) scan was performed at the end of Cycles 2, 4, and 6. Assessment of tumor metabolism was performed by positron emission tomography with 18F-labeled fluorodeoxyglucose (18F-FDG-PET) prior to Cycle 1 and at the time of restaging at the end of Cycles 2 and 4. | ||||
Study Type ICMJE | Interventional | ||||
Study Phase ICMJE | Phase 1 | ||||
Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Sequential Assignment Masking: None (Open Label) Primary Purpose: Treatment | ||||
Condition ICMJE | Neoplasms | ||||
Intervention ICMJE |
| ||||
Study Arms ICMJE |
| ||||
Publications * |
| ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||
Recruitment Information | |||||
Recruitment Status ICMJE | Terminated | ||||
Actual Enrollment ICMJE | 9 | ||||
Original Enrollment ICMJE | 24 | ||||
Actual Study Completion Date ICMJE | May 2007 | ||||
Actual Primary Completion Date | May 2007 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | Inclusion criteria:
Exclusion Criteria
| ||||
Sex/Gender ICMJE |
| ||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||
Accepts Healthy Volunteers ICMJE | No | ||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
Listed Location Countries ICMJE | Australia | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number ICMJE | NCT00293215 | ||||
Other Study ID Numbers ICMJE | LUD2004-015 | ||||
Has Data Monitoring Committee | No | ||||
U.S. FDA-regulated Product |
| ||||
IPD Sharing Statement ICMJE |
| ||||
Responsible Party | Ludwig Institute for Cancer Research | ||||
Study Sponsor ICMJE | Ludwig Institute for Cancer Research | ||||
Collaborators ICMJE | Wyeth is now a wholly owned subsidiary of Pfizer | ||||
Investigators ICMJE |
| ||||
PRS Account | Ludwig Institute for Cancer Research | ||||
Verification Date | July 2020 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |